AbbVie (ABBV) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and AbbVie published the results on October 30, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. AbbVie reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• AbbVie reports a single business segment. The rows above are the therapeutic portfolios in its key product revenue table; the portfolio rows do not add up to total net revenues, which also include other key products such as Mavyret, Creon and Linzess.
• AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026. Acquisition and integration costs in the quarter primarily reflect that deal.

Source: AbbVie Q3 2026 results, October 30, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How AbbVie splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• AbbVie's Immunology revenue was $9.2 billion in Q3 2026, up 16% from $7.9 billion in Q3 2025, 53% of total revenue.
• AbbVie's Neuroscience revenue was $3.4 billion in Q3 2026, up 19% from $2.8 billion in Q3 2025, 19% of total revenue.
• AbbVie's Oncology revenue was $1.7 billion in Q3 2026, up 1% from $1.7 billion in Q3 2025, 10% of total revenue.
• AbbVie's Aesthetics revenue was $1.2 billion in Q3 2026, down 1% from $1.2 billion in Q3 2025, 7% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

AbbVie's release gives an outlook for adjusted diluted EPS only. It gives no revenue figure for the coming quarter or the year.

In its Q3 2026 release, AbbVie said:

“AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026.”

“The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.”

Source: AbbVie Q3 2026 release, Oct 30, 2026.

This is the company's own guidance as of Oct 30, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the ABBV forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net revenues and diluted EPS, each as first reported in that quarter's release. AbbVie's GAAP EPS swings with acquired IPR&D and milestones expense and changes in the fair value of contingent consideration, which is why it ranges from $0.10 to $2.37 across these five quarters.

We do not hold a confirmed date for AbbVie's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 30, 2026

AbbVie reports one business segment and breaks its net revenues into therapeutic portfolios. Of $17,404 million in Q3 2026, immunology brought in $9,165 million, neuroscience $3,389 million, oncology $1,696 million and aesthetics $1,176 million. U.S. net revenues were $13,333 million and international net revenues $4,071 million. (AbbVie Q3 2026 release, Oct 30, 2026)

Within AbbVie's immunology portfolio, Skyrizi net revenues were $5,776 million, up 22.7%, and Rinvoq $2,706 million, up 23.9%, which AbbVie attributes to continued strong market share uptake and market growth across all indications. Humira fell 31.2% to $683 million, which AbbVie puts down to the continued impact of direct biosimilar competition following the loss of exclusivity. (AbbVie Q3 2026 release, Oct 30, 2026; AbbVie Form 10-Q, Q3 2026, Nov 3, 2026)

Neuroscience grew 19.4%. Botox Therapeutic was $1,080 million, Vraylar $1,068 million, Ubrelvy $449 million and Qulipta $398 million, and Vyalev rose to $286 million from $138 million a year earlier on what AbbVie calls strong demand uptake. AbbVie says favorable pricing also helped Vraylar and Ubrelvy. (AbbVie Q3 2026 release, Oct 30, 2026; AbbVie Form 10-Q, Q3 2026, Nov 3, 2026)

Oncology was up 0.8%: Venclexta rose 10.7% to $803 million while Imbruvica fell 26.1% to $522 million on unfavorable pricing and lower U.S. demand. Aesthetics fell 1.4% to $1,176 million. Botox Cosmetic rose 4.9% to $669 million and Juvederm fell 11.9% to $222 million, which AbbVie attributes to decreased consumer demand and unfavorable pricing. (AbbVie Q3 2026 release, Oct 30, 2026; AbbVie Form 10-Q, Q3 2026, Nov 3, 2026)

In the United States AbbVie sells mostly through wholesalers. In 2025 three of them, McKesson, Cardinal Health and Cencora, accounted for substantially all of AbbVie's U.S. pharmaceutical product sales, and none accounted for more than 43% of its 2025 U.S. gross revenues. (AbbVie Form 10-K, 2025, Feb 20, 2026)

AbbVie's GAAP diluted EPS was $2.37 in Q3 2026 and its adjusted diluted EPS $3.82. The largest items between the two were intangible asset amortization of $1,669 million pre-tax ($0.79 per share), the change in fair value of contingent consideration of $829 million ($0.46) and acquisition and integration costs of $408 million ($0.22), primarily for Apogee Therapeutics. Acquired IPR&D and milestones expense of $216 million stays in both figures and cost $0.11 per share. (AbbVie Q3 2026 release, Oct 30, 2026)

AbbVie's Q3 2025 GAAP EPS of $0.10 included $2.7 billion of acquired IPR&D and milestones expense, an unfavorable impact of $1.50 per share, and $847 million of impairment charges on the Resonic and Durysta intangible assets. The GAAP tax rate was 12.6% in Q3 2026 against 73.7% a year earlier; the adjusted tax rate was 13.6%. (AbbVie Q3 2026 release, Oct 30, 2026)

AbbVie's weighted-average diluted share count was 1,772 million in both quarters. It repurchased 5 million shares for $1.1 billion in the first nine months of 2026 and had about $1.8 billion of repurchase authorization left at September 30, 2026. It paid $135.11 per share in cash for Apogee, total consideration of $10.6 billion, and recorded $318 million of post-closing expense for Apogee employee awards in the quarter. (AbbVie Form 10-Q, Q3 2026, Nov 3, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

AbbVie's outlook covers adjusted diluted EPS for the full year and nothing else: its release gives no revenue figure. With Q3 2026 results it raised the 2026 range from $13.76 - $13.96 to $13.95 - $13.99. The range includes the $0.69 per share of acquired IPR&D and milestones expense booked through the third quarter and excludes any such expense after it, which AbbVie says it cannot reliably forecast. (AbbVie Q3 2026 release, Oct 30, 2026)

AbbVie also raised its quarterly dividend from $1.73 to $1.82 per share, about 5.2%, beginning with the dividend payable on February 16, 2027. (AbbVie Q3 2026 release, Oct 30, 2026)

A consensus figure is the average of the models published by the analysts who cover AbbVie, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones AbbVie's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning ABBV is on is ABBV a buy or a sell?, what analysts expect next is on the ABBV forecast, and what the company does is on the AbbVie (ABBV) stock page.

Every number on this page can be traced to a document AbbVie published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.